Large language models trained on vast datasets could speed genomics research, streamline clinical documentation, improve real-time diagnostics, support clinical decision-making, accelerate drug ...

Prefer Newsweek on Google to see more of our trusted coverage when you search. In 2025, biotechnology stocks had their best year since the COVID-19 pandemic, with the market sector’s two major indexes ...

Marc Cummings, president and CEO of Life Science Washington, speaking at a one-day forum focused on AI-driven biotech that was held in Seattle in October 2025. (Life Science Washington Photo) Seattle ...

Over the last couple of weeks, the biotech and pharma spaces have been inundated with product launches, partnership announcements, grant awards and breakthrough publications. Here, we highlight an AI ...

Biotech stocks saw a major rebound in 2025, with key indexes significantly outperforming the S&P 500. Private investment in longevity science doubled in 2024, highlighting growing interest in ...

Molecular glue-focused biotech f5 Therapeutics has failed to stick around for the long haul, shuttering after six years, according to an announcement from the company’s CEO on LinkedIn. “The past few ...

(RTTNews) - IO Biotech (IOBT) has opened the door to a potential merger, asset sale, or even dissolution as it evaluates "a range of strategic alternatives," a move that underscores the pressure ...

For years, public debate around U.S. dependence on China has focused on semiconductors, consumer electronics, rare earth minerals and industrial manufacturing. Far less attention has been paid to a ...

Why personalized gene editing, genetic resurrections and embryo scoring made our list. Earlier this week, MIT Technology Review published its annual list of Ten Breakthrough Technologies. As always, ...

2025 proved a turning point year for the biotech industry, albeit one wrought with contradiction. The post-COVID slump experienced by the industry seemed due to continue, with the sweeping cuts to the ...

Biotech IPOs hit lowest level in over a decade in 2025 Investors focus on biotechs with mature pipelines and positive trial data Lower interest rates and capital inflows expected to boost sector Jan ...